大洋洲 · 股市与财经 · Stockhead
Alterity’s biomarker-adjusted Phase 2 analysis shows ~52pc slowing of MSA decline
The analysis also showed that a biomarker of disease severity predicted how quickly patients declined. ... Read More The post Alterity’s biomarker-adjusted Phase 2 analysis shows…
在 Stockhead 阅读全文 登录后可收藏MediaNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (stockhead.com.au)
